| Literature DB >> 30355988 |
Patrick Rider1, Željka Perić Kačarević2, Said Alkildani3, Sujith Retnasingh4, Reinhard Schnettler5, Mike Barbeck6.
Abstract
Three-dimensional (3D) printing has become an important tool in the field of tissue engineering and its further development will lead to completely new clinical possibilities. The ability to create tissue scaffolds with controllable characteristics, such as internal architecture, porosity, and interconnectivity make it highly desirable in comparison to conventional techniques, which lack a defined structure and repeatability between scaffolds. Furthermore, 3D printing allows for the production of scaffolds with patient-specific dimensions using computer-aided design. The availability of commercially available 3D printed permanent implants is on the rise; however, there are yet to be any commercially available biodegradable/bioresorbable devices. This review will compare the main 3D printing techniques of: stereolithography; selective laser sintering; powder bed inkjet printing and extrusion printing; for the fabrication of biodegradable/bioresorbable bone tissue scaffolds; and, discuss their potential for dental applications, specifically augmentation of the alveolar ridge.Entities:
Keywords: 3D printing; additive manufacturing; bone augmentation; bone regeneration; bone scaffold; dentistry
Mesh:
Year: 2018 PMID: 30355988 PMCID: PMC6274711 DOI: 10.3390/ijms19113308
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Xenogeneic bone graft (Cerabone®) showing seamless tissue integration. Arrows are used to highlight the bone graft/host bone tissue interface.
Figure 2Alveolar ridge augmentation using an additively manufactured bone tissue scaffold. (1) a bone defect has formed in the alveolar ridge; (2) a bone scaffold is designed and then printed using additive manufacturing technology; (3) the printed bone scaffold is placed in the defect space to support bone regeneration; (4) new bone infiltrates the scaffold, eventually degrading or resorbing the structure; and, (5) a dental implant in positioned in the regenerated bone.
Figure 3Schematic of stereolithography (SLA) printing process. The laser source cures the top of the liquid resin in a predetermined pattern. The platform is then lowered by the height of the cured resin and the process is repeated.
Summary of SLA Scaffold Properties.
| Material | Scaffold Mechanical Properties | Porosity (%) | Cell Viability | References |
|---|---|---|---|---|
| GelMA (Irgacure 2959) | 30 kPa * at the highest degree of methacrylation | Non-porous | Highest cell viability was reported in the lowest concentration of GelMA, 80–95% | [ |
| SilMA (LAP) | 910 kPa ** at the highest percentage of Sil-MA | / | SilMA exhibited similar absorbance in a cck-8 assay as GelMA | [ |
| GelMA:SF (Irgacure 2959) | Reached 75 kPa ** with the highest concentration of SF | 41.8 | Highest OD values was over 2.0, a little bit higher than the metabolic activity of pure GelMA | [ |
| Chitosan:PEGDA (Irgacure 819) | ~1000 kPa * at the highest concentration of PEGDA | Non-porous | Ratios of 1:5 and 1:10 of Chitosan:PEGDA exhibited the highest cell viability percentages 93–97% | [ |
| Methacry. PCL/BG (Lucirin TPO-L) | 3.4 MPa/dry * | 63 | Highest metabolic activity at highest BG concentration | [ |
| CP CP/PCL | 2.04 ± 0.12 MPa ** | / | CP:PCL had lower proliferation than pure CP but exhibited higher osteogenic markers expression | [ |
| Methacrylated Alginate (VA-086) | 3.3–12.4 kPa ** | Non-porous | 75% at moderate stiffness | [ |
| Methacrylated PCL (Irgacure 2959, 369) | 2.02 ± 2.87 MPa ** | 70.5 ± 0.8 | Similar metabolic activity as in tissue culture polystyrene | [ |
| PETMP:PEG-DVE | 6.9 ± 1.8 MPa * | Non-porous | 95% viability was exhibited in 120 h | [ |
| Methacrylated PLA (camphorquinone) | 9.43 ± 3.2 MPa with intermediate content of HA and highest content of TEGDMA (flexural strength) | / | Samples with highest TEGDMA and HA content exhibited better cell viability. | [ |
| PTMC/HA (Lucirin TPO-L) | / | 70 | Addition of HA and TEGDMA promoted better cell attachment and proliferation | [ |
* Modulus, ** Strength. Abbreviations: β-TCP: β-tricalcium phosphate, BG: bioglass, GelMA: gelatin methacrylate, HA: hydroxyapatite, PEGDA: polyethylene glycol diacrylate, PEG-DVE: poly(ethylene glycol) divinyl ether, PETMP: pentaerythritol tetrakis(3-mercaptopropionate), PCL: polycaprolactone, PPF: polypropylene fumarate, SilMA: silk methacrylate, SF: silk fibroin, TEGDMA: triethylene glycol dimethacrylate.
Figure 4Schematic of selective laser sintering (SLS) process. A laser source sinters/melts the top layer of powder in a powder bed in a predetermined pattern. The powder bed is lowered in height and a fresh layer of powder is positioned on top via a leveling roller. The process is then repeated.
Summary of SLS Scaffold Properties.
| Material | Scaffold Compressive Strength (MPa) | Porosity (%) | Biological Response | References |
|---|---|---|---|---|
| Magnesium silicate (Mg2SiO4) | 40.29 ± 1.32 MPa | / | / | [ |
| β-TCP/ZnO | 17.89 MPa with 2.5 wt % ZnO | 56.8 | MG-63 cells indicated better attachment and proliferation with increased ZnO | [ |
| HA/β-TCP | 18.35 MPa with 30 wt % β-TCP | ~61 | MG-63 cells exhibited better attachment and morphology on scaffolds with 30 wt % and 50 wt % | [ |
| PCL | 2.3 MPa | 50 | Implanted in minipigs, exhibited full healing in 3 months | [ |
| PCL/β-TCP | 6 MPa * with 10 wt % β-TCP | 68 | Pure β-TCP exhibited better ingrowth than polymer/ceramic composite | [ |
| PCL/HA | 3.17 MPa with 15 wt % HA | 70.31 | PCL/HA scaffolds exhibited better bioactivity than pure PCL after 28 days | [ |
| PHBV/CP | 0.55 MPa with 15 wt % CP | 62.6 ± 1.2 | The incorporation of CP nanoparticles significantly improved cell proliferation and alkaline phosphatase activity | [ |
| PLLA/CHA | Over 0.6 MPa with 10 wt % CHA | 66.8 ± 2.5 | Cellular response similar to pure PLLA | [ |
* Effective modulus. Abbreviations: β-TCP: β-tricalcium phosphate, HA: hydroxyapatite, PCL: polycaprolactone, PHBV: poly(hydroxybutyrate-co-hydroxyvalerate), CP: calcium phosphate, PLLA: poly(l-lactic acid), CHA: carbonated hydroxyapatite.
Figure 5Schematic of Two Different Inkjet Printing Mechanisms over a powder bed: 1. Thermal-based, 2. Piezoelectric-based. The inkjet printheads dispense a binding solution to the powder bed below. The powder bed is lowered in height and a fresh layer of powder is positioned on top via a leveling roller. The process is then repeated.
Summary of Inkjet Printed Scaffold Properties.
| Material | Binder | Porosity (%) | Compressive Strength (MPa) | Biological Response | References |
|---|---|---|---|---|---|
| HA | phosphoric acid 10% + 1 M NaH2PO4 | 60 | 1.9 ± 0.2 | Implanted into mice, there was minimal tissue penetration. | [ |
| α-TCP | Sodium chondroitin sulfate 5% + disodium succinate 12% | 61 | 18.6 | Implanted into beagle dogs, experienced bony bridging, bone formation and the presence of bone marrow. | [ |
| β-TCP | Phosphoric acid 1 wt % | / | 2.5 | Cranial plates implanted into mice, exhibited bone integration around edges and fibrous tissue in center. | [ |
| β-TCP | Phosphoric acid 5 wt % | 53 | 0.9 ± 0.1 | When implanted, monetite and brushite degraded faster than the β-TCP | [ |
| BCP (HA/β-TCP) | |||||
| 100:0 | PVA 0.6 wt % | 42 ± 2 | 1.54 ± 0.13 | Seeded with BMSCs, proliferation was highest for a HA/β-TCP ratio of 60:40 for both binder solutions. The scaffolds made with a PVA binder showed higher proliferation rates compared to the phosphoric acid samples. | |
| Phosphoric acid 8.75 wt % | 28 ± 2 | 2.81 ± 0.08 | |||
| 20:80 | PVA 0.6 wt % | 44 ± 2 | 1.21 ± 0.11 | ||
| Phosphoric acid 8.75 wt % | 49 ± 3 | 2.36 ± 0.18 | [ | ||
| 40:60 | PVA 0.6 wt % | 43 ± 3 | 1.26 ± 0.09 | ||
| Phosphoric acid 8.75 wt % | 47 ± 2 | 2.57 ± 0.23 | |||
| 60:40 | PVA 0.6 wt % | 42 ± 1 | 1.35 ± 0.11 | ||
| Phosphoric acid 8.75 wt % | 49 ± 3 | 2.66 ± 0.20 | |||
| TTCP | Phytic acid 25 wt % | 39.4 ± 1.5 | 1.3 ± 0.2 | / | [ |
| Brushite | Phosphoric acid 20 wt % | 38.8 | 23.4 ± 3.3 | Showed good biocompatibility when seeded with osteoblastic cells. | [ |
| Phosphoric acid 20 wt % | 45 | 5.3 ± 0.6 | When implanted, degraded slower than monetite samples, and over a 4-week period developed HA phases. | [ | |
| Monetite | Phosphoric acid 20 wt % | 43.8 | 15.3 ± 1.1 | Showed good biocompatibility when seeded with osteoblastic cells. | [ |
| Phosphoric acid 20 wt % | 44 | 15 * | After 8 weeks implanted into rabbits, had completely integrated/resorbed into native bone. | [ | |
| Calcium Sulfate | 2-pyrrolidinone | 45.04 | 0.7 | Samples were non-cytotoxic when sintered above 1000 °C. | [ |
| Struvite | Ammonium phosphate | / | 0.23 ± 1.37 | Osteoblastic cells showed good cell viability over 10 days. | [ |
* Immersion treatment, ** Sintered. Abbreviations: α-TCP—alpha-tricalcium phosphate, β-TCP: β-tricalcium phosphate, BCP: biphasic calcium phosphate, BMSCs: bone marrow mesenchymal stem cells, HA: hydroxyapatite, TTCP: tetracalcium phosphate.
Figure 6Comparison of two different xenogeneic bone graft materials: (A) sintered xenograft (Cerabone®) and (B) non-sintered xenograft (BioOss®). For example, xenograft (A) has a rougher surface in comparison to xenograft (B).
Figure 7Schematic of extrusion based printing. A liquid resin is extruded in the form of a filament into a predetermined pattern.
Summary of Extrusion Printed Scaffold Properties.
| Material | Porosity (%) | Compressive Strength (MPa) | Biological Response | References |
|---|---|---|---|---|
| Pluronic F-127 hydrogel | / | 50 MPa | / | [ |
| PLA | 40% | 45.61 MPa | Metabolic activity and proliferation rate of osteosarcoma cells MG-63 did not have significant differences between each porosity. | [ |
| PLA | 50–60% | 29.96 MPa | ||
| PLA | 60 ± 1.5% | 9.47 MPa | Better seeding and metabolic activity with collagen/dopamine coating | [ |
| PLA | 55% | 13.25 ± 1.6 | Scaffolds with 66% porosity exhibited higher cell count | [ |
| 60% | 9.47 ± 0.47 | |||
| 66% | 5.57 ± 0.27 | |||
| PBT | 62.11 ± 0.36% | 10.44 ± 2.09 MPa | / | [ |
| PLGA/PCL | 69.6% | 12.9 MPa | Mesenchymal stem cells demonstrated good proliferation rates | [ |
| PCL | 61 ± 1% | Dry 41.9 ± 3.5 MPa | Human fibroblasts and osteoprogenitor cells proliferated, differentiated and deposited ECM | [ |
| PCL | 54.9% | / | Cardiomyoblasts attached to the structure, although a pore size of 250µm did not allow for cells to migrate. | [ |
| PCL/HA/(0.2%) CNT | ~40% | / | Higher concentrations of CNT enhanced cell adhesion and spreading of MG-63 cells | [ |
| TCP/AA 60/40-GO | / | / | Over a 21-day period, human osteoblasts had secreted mineral deposits | [ |
| β-TCP | 49% | 20 ± 2 MPa | / | [ |
| Sr-HT-Gahnite | 66.1% | 53 ± 9 MPA | / | [ |
| 52.1% | 121 ± 12 MPa | |||
| 48.5% | 140 ± 15 MPa |
AA: alginic acid, CNT: carbon nanotube, PBT: polybutylene terephthalate, PCL: polycaprolactone, PLA: polylactic acid, PLGA: poly (DL-lactide-co-glycolide), PPF: poly (propylene fumarate).